1. No category

MONDAY, August 31st
SESSION 1 – Toxicokinetics I
9.30-11.00 am
MOP 1
TOXICOKINETICS OF NEW PSYCHOACTIVE SUBSTANCES: DETERMINATION OF THEIR
PLASMA PROTEIN BINDING AND ITS USE IN CALCULATING METABOLIC STABILITY
Meyer M.R.([email protected])*, Leibnitz S., Maurer H.H.
MOP 2
CROCODILE: METABOLISM OF DESOMORPHINE IN HUMAN LIVER MICROSOMES, HUMAN
HEPATOCYTE CULTURES, AND RAT URINE AS WELL AS ITS DETECTABILITY USING
STANDARD URINE SCREENING APPROACHES
Richter L.H.J.([email protected])*, Kaminski Y.R., Klein S., Noor F., Meyer M.R., Maurer H.H.
MOP 3
STUDIES ON THE STABILITY OF COCAINE, MDMA, MDEA, AND THEIR MAIN HUMAN URINARY METABOLITES IN WASTEWATER BY HILIC LC-MS/MS, USING POOLED HUMAN
URINE AND URINATED SOIL SAMPLES
Mardal M.([email protected])*, Kinyua J., Bram M., Maho W., Van Nuijs A., Covaci A., Maurer H.H.,
Meyer M.R.
MOP 4
METABOLISM OF THE DESIGNER DRUG PMMA (4-METHOXYMETHAMPHETAMINE) IN
HUMAN LIVER MICROSOMES
Vevelstad M.([email protected])*, Øiestad E.L., Nerem E., Arnestad M., Bogen I.L.
MOP 5
METABOLISM OF SYNTHETIC CANNABINOIDS - SIMILARITIES AND DIFFERENCES
BETWEEN METABOLIC PATTERNS OF DIFFERENT STRUCTURAL SUBCLASSES
Franz F.([email protected])*, Schwörer N., Angerer V., Huppertz L.M., Moosmann B.,
Auwärter V.
MOP 6
METABOLIC STUDIES OF SYNTHETIC CANNABINOID PB-22 BY CUNNINGHAMELLA
ELEGANS
Watanabe S.([email protected])*, Kuzhiumparambil U., Winiarski Z., Fu S.
MOP 7
STUDY ON BEHAVIORAL AND PHARMACOKINETIC PROPERTIES OF 5,6METHYLENEDIOXY-2-AMINOINDANE (MDAI) INCLUDING BIOTRANSFORMATION IN RATS
AFTER A SUBCUTANEOUS BOLUS DOSE
Zidkova M.([email protected])*, Palenicek T., Lhotkova E., Linhart I., Himl M., Balikova M.
SESSION 2 – Alcohol Use Markers
11.30 am – 1.00 pm
MOP 8
ETHYL 4-HYDROXYBUTYRATE – SEARCH FOR A LONG-TERM MARKER OF COMBINED
GAMMA-BUTYROLACTONE (GBL) AND ALCOHOL UPTAKE
Wilde M.([email protected])*, Angerer V., Franz F., Auwärter V., Moosmann B.
MOP 9
FORMATION AND INHIBITION OF ETHYL GLUCURONIDE AND ETHYL SULFATE
Skopp G.([email protected])*, Stachel N.
MOP 10
DEVELOPMENT OF A STANDARDISED TEST FOR THE ACTIVITY OF THE ENZYME
PHOSPHOLIPASE D (PLD), RESPONSIBLE FOR BIOSYNTHESIS OF THE ALCOHOL
BIOMARKER PHOSPHATIDYLETHANOL (PETH)
Schroeck A.([email protected])*, Bütikofer P., Weinmann W.
MOP 11
OBSERVATIONS ON THE SAMPLING OF NON-VOLATILES IN EXHALED BREATH –
DETECTION OF PHOSPHATIDYLETHANOL
Beck O.([email protected])*, Ullah S., Danielson Å., Helander A.
MOP 12
AUTO-BREWERY SYNDROME AS A POSSIBLE EXPLANATION FOR INCREASED ALCOHOL
BIOMARKERS?
Boettcher M.([email protected])*, Helander A., Picht F., Beck O., Boettcher--Lorenz
J., Keller T.
MOP 13
A NOVEL, SIMULTANEOUS EXTRACTION OF FAEE AND ETG FROM MECONIUM AND
ANALYSIS BY LC-MS/MS
Vaiano F.([email protected])*, Favretto D., Del Bravo E., Palumbo D., Mari F., Bertol E.
MOP 14
KINETICS OF ETG IN FINGERNAILS IN A GROUP OF CHRONIC HEAVY DRINKERS
Morini L.([email protected])*, Hoiseth G., Giarratana N., Groppi A
SESSION 3 – New Psychoactive Substances (intoxication
cases and identification)
2.30 pm – 4.00 pm
MOP 15
DETERMINATION OF NEWLY ENCOUNTERED DESIGNER DRUGS α-PHP AND
ACETYLFENTANYL IN AN ACUTE INTOXICATION CASE BY LC/Q-TOFMS
Hisatsune K.([email protected])*, Zaitsu K., Kusano M., Yamanaka M., Nakajima J., Moriyasu T., Ishiba A.,
Hida M., Tsuchihashi H., Ishii A.
MOP 16
THREE DEATHS INVOLVING SYNTHETIC CANNABINOID- PB-22 (1-PENTYL-8-QUINOLINYL
ESTER-1H-INDOLE-3-CARBOXYLIC ACID)
Pricone M.G.([email protected])*, Yap S., Gerostamoulos D., Drummer O.H., Woodford N.W.
MOP 17
DEATH AFTER CONSUMPTION OF NEW SYNTHETIC CANNABINOIDS AND ALCOHOL
Ewald A.([email protected])*, Schaefer N., Peters B., Schmidt P.
MOP 18
A FATAL INTOXICATION RELATED TO MDPV AND PENTEDRONE COMBINED WITH ANTI
PSYCHOTIC AND ANTIDEPRESSANT SUBSTANCES IN CYPRUS
Liveri K.([email protected])*, Constantinou M., Afxentiou M., Kanari P.
MOP 19
MEPHEDRONE IN POST-MORTEM CASES: A 5 YEAR REVIEW
Hockenhull J.([email protected])*, Paterson S.
MOP 20
DETECTION OF 31 STIMULANT, PSYCHEDELIC AND DISSOCIATIVE DESIGNER DRUGS IN
REAL HAIR SAMPLES
Salomone A., Gazzilli G., Di Corcia D., Gerace E.([email protected])*, Vincenti M.
MOP 21
METHODS DEVELOPMENT FOR THE ASSESSMENT OF NPS USE BY ANALYSIS OF
DIFFERENT BIOLOGICAL SAMPLES: HAIR, BLOOD AND URINE
Odoardi S., Anzillotti L., Fisichella M., Strano Rossi S.([email protected])*
SESSION 4 - Toxicokinetics II
4.30 pm - 6.00 pm
MOP 22
METABOLISM OF MAJOR PHYTOCANNABINOIDS BY HUMAN PLACENTA MICROSOMES
AND CYP19
Watanabe K.([email protected])*, Inoue K., Murai M., Usami N., Yamaori S., Yamamoto I.
MOP 23
METABOLISM OF 25I-NBOME AND 25C-NBOME, TWO SYNTHETIC HALLUCINOGENS, IN
MICE AND CORRELATION WITH AUTHENTIC HUMAN URINE SAMPLES
Wohlfarth A.([email protected])*, Roman M., Karlsson M., Andersson M., Kugelberg F., Huestis
M.A., Kronstrand R.
MOP 24
IN VITRO METABOLISM STUDIES AND LC-MS CHARACTERIZATION OF SARM LG121071
FOR ROUTINE DOPING CONTROL
Knoop A.([email protected])*, Krug O., Vincenti M., Schänzer W., Thevis M.
MOP 25
INHIBITION POTENTIAL OF MDMA AND ITS RELEVANT METABOLITES ON THE IN VITRO
DEAMINATION OF SEROTONIN AND DOPAMINE
Steuer A.E., Boxler M.I.([email protected])*, Stock L., Kraemer T.
MOP 26
PHARMACOKINETIC MODELLING OF JWH-210, RCS-4, AND THC IN PIG SERUM AFTER
INTRAVENOUS ADMINISTRATION
Schaefer N.([email protected])*, Wojtyniak J.G., Kettner M., Schlote J., Laschke M., Ewald A., Lehr
T., Menger M., Maurer H., Schmidt P.
MOP 27
THE USE OF CYTOCHROME P450 2D6 AND 2C19 GENOTYPING FOR TOXICOLOGICAL
INTERPRETATION OF SPECIAL FORENSIC CASES – USEFUL OR NOT?
Ross Jornil J.(
[email protected])*, Vukelic Andersen L.
MOP 28
ENANTIOSELECTIVE PHARMACOKINETICS OF TRAMADOL AND ITS THREE MAIN
METABOLITES; IMPACT OF CYP2D6 AND CYP2B6 GENOTYPE
Haage P.([email protected])*, Kronstrand R., Josefsson M., Zackrisson A., Kugelberg F.C.
TUESDAY, September 1st
SESSION 1 – Driving under the Influence I
8.30-10.30 am
TuOP 1
EVALUATION OF DELTA-9-TETRAHYDROCANNABINOL CONCENTRATIONS IN DUID
INVESTIGATION CASES AND CONSEQUENCES OF VARIOUS THC PER SE THRESHOLDS.
Chan-Hosokawa A.([email protected])*, Logan B.K.
TuOP 2
GHB IN SUSPECTED IMPAIRED DRIVERS IN THE NETHERLANDS AND A COMPARISON
WITH POSTMORTEM CASES.
Smink B.([email protected])*, Verschraagen M., Maes A.
TuOP 3
PREVALENCE OF NEW PSYCHOACTIVE SUBSTANCES IN DRUG DRIVERS IN SCOTLAND A 2 YEAR REVIEW
Officer J.([email protected])*
TuOP 4
CRASH RISK OF MEDICINAL DRUGS
Drummer O.([email protected])*, Yap S.
TuOP 5
DRIVING UNDER THE INFLUENCE OF MARIJUANA VERSUS DRIVING AND DYING UNDER
THE INFLUENCE OF MARIJUANA: A COMPARISON OF BLOOD CANNABINOID
CONCENTRATIONS IN ARRESTED DRIVERS VERSUS DECEASED DRIVERS
San Nicolas A., Volk J.A., Knight J.E., Ingle E.A., Williams C.M., Lemos N.P.([email protected])*
TuOP 6
DRIVING UNDER THE INFLUENCE OF ALCOHOL AMONG CAR DRIVERS IN ISRAEL
Schallmach E.([email protected])*, Gopher A., Rotenberg M.
TuOP 7
IS THC-COOH-GLUCURONIDE A USEFUL MARKER FOR TETRAHYDROCANNABINOL (THC)
IN DUID CASES? RETROSPECTIVE DATA ANALYSIS ON UPLC-HR-TOFMS DATA FILES
FROM 2 YEARS OF DUID CASES
Telving R.([email protected])*, Hasselstrøm J.B., Andreasen M.F.
TuOP 8
DRIVING UNDER THE INFLUENCE OF ALCOHOL AND ILLICIT DRUGS. A FIVE-YEAR STUDY
ON 6500 DRIVERS INVOLVED IN ROAD ACCIDENTS IN NORTH-EAST ITALY
Zancanaro F.([email protected])*, Frison G., Tedeschi G., Frasson S., Zamengo L., Zancaner
S., Sciarrone R.
SESSION 2 - Antidoping
11.00 am – 1.00 pm
TuOP 9
LIPOSOMES AS DRUG DELIVERY SYSTEMS IN SPORT DOPING: RECENT ADVANCES IN
THE STUDY OF LIPOSOME VEHICULATED HEMOGLOBINS
Colicchia S., Botre F.([email protected])*, De La Torre X., Esposito S., Iannella L., Donati F.
TuOP 10
"DILUTE-AND-INJECT" MULTI-TARGET SCREENING ASSAY FOR (NOVEL) HIGHLY POLAR
DOPING AGENTS USING HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY HIGH
RESOLUTION/HIGH ACCURACY MASS SPECTROMETRY FOR SPORTS DRUG TESTING.
Görgens C.([email protected])*, Guddat S., Orlovius A.K., Sigmund G., Dib J., Thevis M.,
Schänzer W.
TuOP 11
APTAMER BASED DETECTION OF PEPTIDE AND PROTEIN DOPING THREATS IN SPORT
USING GONADOTROPIN-RELEASING HORMONE AND ERYTHROPOIETIN AS MODEL
COMPOUNDS
Richards S.L.([email protected])*, Cawley A.T., Raftery M.J., Cavichioli R.
TuOP 12
ISOLATION, ENRICHMENT AND DETECTION OF ERYTHROPOIETIN MIMETIC AGENTS
FROM HUMAN URINE BY MEANS OF EPO-RECEPTOR-PURIFICATION AND LC-HR-MS/MS
DETERMINATION
Vogel M.([email protected])*, Thomas A., Schänzer W., Thevis M.
TuOP 13
FULL-LENGTH MGF AND XENON - NEW ADDITIONS TO ANTI-DOPING TEST PROGRAMS
Thevis M.([email protected])*
TuOP 14
ADIPOR AGONISTS AND THEIR IMPLEMENTATION IN SPORTS DRUG TESTING
Dib J.([email protected])*, Schlörer N., Schänzer W., Thevis M.
TuOP 15
MYOSTATIN INHIBITORS IN SPORTS DRUG TESTING: DETECTION OF MYOSTATINNEUTRALIZING ANTIBODIES IN PLASMA SAMPLES BY USING IMMUNOAFFINITY
PURIFICATION AND WESTERN BLOTTING
Walpurgis K.([email protected])*, Thomas A., Schaenzer W., Thevis M.
TuOP 16
INNOVATIVE CHEMOMETRIC APPROACHES AS POWERFUL TOOLS IN THE ATHLETE
BIOLOGICAL PASSPORT
Alladio E., Caruso R., Gerace E., Salomone A.([email protected])* Vincenti M.
TuOP 17
DRUG-DRUG INTERACTIONS AND MASKING EFFECTS IN SPORT DOPING: THE
CONTRIBUTION FROM IN VITRO STUDIES COUPLED TO CHROMATOGRAPHY-MASS
SPECTROMETRY
Palermo A.([email protected])*, Botre F., De La Torre X., Fiacco I., Iannone M., Mazzarino M.
SESSION 3 – Toxicokinetics III
2.30 pm - 4.00 pm
TuOP 18
EVALUATION OF THE BINDING AFFINITIES OF 54 NEWLY-EMERGED SYNTHETIC
CANNABINOIDS AT THE CANNABINOID CB1 AND CB2 RECEPTORS
Kikura-Hanajiri R.([email protected])*, Uchiyama N., Hakamatsuka T.
TuOP 19
CB1 AND CB2 RECEPTOR AFFINITIES OF SYNTHETIC CANNABINOIDS ON THE ILLICIT
DRUG MARKET
Heß C.([email protected])*, Schoeder C., Müller C., Madea B.
TuOP 20
CYP2D6 GENOTYPE-DEPENDING CHIRAL PHARMACOKINETICS AND PHASE I AND II
METABOLISM OF MDMA AFTER CO-ADMINISTRATION OF BUPROPION IN A CONTROLLED
STUDY IN HUMANS
Steuer A.E.([email protected])*, Schmidhauser C., Tingelhoff E., Schmid Y., Rickli A., Liechti M.E.,
Kraemer T.
TuOP 21
HEROIN KINETICS IN BLOOD AND VITREOUS HUMOR IN A LIVING PIG MODEL
Høiseth G. ([email protected])*, Gottås A., Arnestad M., Halvorsen S., Bachs L.
TuOP 22
SEROTONIN TOXICITY AND CYTOCHROME P450 GENETIC POLYMORPHISMS
Gunja N.([email protected])*, Mann G., Piatkov I.
TuOP 23
FIRST METABOLIC PROFILE OF PV8, A NOVEL SYNTHETIC CATHINONE, BY HIGHRESOLUTION MASS SPECTROMETRY (HRMS)
Swortwood M.([email protected])*, Ellefsen K., Wohlfarth A., Concheiro M., Huestis M.
TuOP 24
FLUBROMAZOLAM - CHARACTERIZATION AND BASIC PHARMACOKINETIC EVALUATION
OF A HIGHLY POTENT DESIGNER BENZODIAZEPINE
Huppertz L.([email protected])*, Franz F., Bisel P., Moosmann B., Auwärter V.
SESSION 4 – Toxicokinetics IV
4.30 pm – 6.00 pm
TuOP 25
SEQUENCING CYP2D6 IN POST-MORTEM BLOOD SAMPLES WITH HIGH CONCENTRATION
OF TRAMADOL FOR THE DETECTION OF *3, *4, *6, *8, *10 AND *12 ALLELES
Fonseca S.([email protected])*, Amorim A., Afonso Costa H., Porto M.J., Franco J., Costa Santos J.,
Dias M.
TuOP 26
POSTMORTEM IDENTIFICATION OF METABOLIZER TYPE: A PROTEOMICS APPROACH
Desharnais B.([email protected])*, Mireault P., Skinner C.D.
TuOP 27
CANNABINOID PHARMACOKINETIC AND BEHAVIOURAL PROFILES AFTER DIFFERENT
ROUTES OF ADMINISTRATION IN RATS
Hložek T.([email protected])*, Balíková M., Pálenícek T., Lhotková E., Kaderábek L., Tylš F., Šíchová K.,
Štefková K., Uttl L.
TuOP 28
CONTROLLED VAPORIZED CANNABIS, WITH AND WITHOUT ALCOHOL: SUBJECTIVE
EFFECTS AND BLOOD CANNABINOID DISPOSITION
Hartman R.L.([email protected])*, Brown T.L., Milavetz G., Spurgin A., Gorelick D.A., Gaffney G.,
Huestis M.A.
TuOP 29
GHB AND ITS NEWLY DESCRIBED METABOLITE GHB-β-O-D-GLUCURONIDE –
DISCRIMINATION EXOGENOUS/ENDOGENOUS VIA LC/MS/MS AND GC/C/IRMS
Mehling L.M.([email protected])*, Lott S., Maas A., Madea B., Mußhoff F., Piper T.,
Thevis M., Spottke A., Heß C.
TuOP 30
EVALUATION OF THE DNA DAMAGING POTENTIAL OF ANTIDOTE OXIME K048 IN A549
AND HACAT CELL LINES
Lucic Vrdoljak A.([email protected])*, Šegvic Klaric M., Zunec S., Milic M., Kopjar N.
TuOP 31
BEHAVIOURAL AND PHARMACOLOGICAL CHARACTERIZATION OF A NOVEL
CANNABIMIMETIC ADAMANTANE-DERIVED INDOLE, APICA, AND CONSIDERATIONS ON
THE POSSIBLE MISUSE AS A PSYCHOTROPIC SPICE ABUSE, IN C57BL/6J MICE
Malta G.([email protected])*, Argo A., Brancato A., Roda G., Casagni E., Gambaro V., Procaccianti
P., Cannizzaro C.
WEDNESDAY, September 2nd
SESSION 1 – Driving under the Influence II
8.30 - 10.30 am
WOP 1
COMPARISON OF ILLICIT DRUG CONCENTRATIONS IN PLASMA AFTER ROADSIDE
TESTING IN URINE OR ORAL FLUID IN THE BELGIAN DRIVING POPULATION
Van Der Linden T., Wille S.M.([email protected])*, Ramirez Fernandez M.D.M., Verstraete A.G.,
Samyn N.
WOP 2
APPLICATION OF A LC-MS/MS METHOD FOR SELECTED SYNTHETIC CATHINONES AND
PIPERAZINES TO DRIVERS’ ORAL FLUID SPECIMENS
De Castro A.([email protected])*, Lendoiro E., Cruz A., López--Rivadulla M.
WOP 3
ULTRA-RAPID TARGETED ANALYSIS OF 40 DRUGS OF ABUSE IN ORAL FLUID BY LCMS/MS
Di Rago M.([email protected])*, Chu M., Gerostamoulos D., Drummer O.
WOP 4
TIME LAPSE PERIOD OF POSITIVITY OF ORAL-FLUID TEST IN CHRONIC AND
OCCASIONAL CONSUMERS AFTER ADMINISTRATION OF 10 OR 30 MG OF SMOKED THC
VERSUS PLACEBO; CORRELATION WITH BLOOD CONCENTRATIONS
Alvarez J.C.([email protected])*, Larabi I.A., Ribot M., Mayer C., Knapp A., Quera Salva
M.A., Hartley S.
WOP 5
OPTIMIZATION OF AN AUTOMATED SOLID PHASE EXTRACTION TO DETERMINE DRUGS IN
PRESERVED ORAL FLUID USING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY
TANDEM MASS SPECTROMETRY
Ingels A.S.([email protected])*, Ramirez Fernandez M.D.M., Di Fazio V., Wille S.M., Samyn N.
WOP 6
USE OF PSYCHOACTIVE SUBSTANCES AMONG TRUCK DRIVERS IN THE HIGHWAYS OF
THE STATE OF SAO PAULO, BRAZIL
Sinagawa D.M.([email protected])*, Takitane J., Bombana H.S., Carvalho H.B.,
Yonamine M., Rohlfs W.J.C., Prado N.V., Oliveira K.B.G., Muñoz D.R., Leyton V.
WOP 7
CONFIRMATORY AND COMPARATIVE DRUG ANALYSIS OF ORAL FLUID / BLOOD
SPECIMENS FROM DRIVERS
Stoykova S.([email protected])*, Atanasov V.
WOP 8
ASSOCIATION BETWEEN ELEVATED HAIR ETG AND ALCOHOL RELATED TRAFFIC
DEATHS
Gottardo R.([email protected])*, Sorio D., Bertaso A., Tagliaro F.
SESSION 2 – Poisoning Case Reports
11.00 am – 12.45 pm
WOP 9
DATURA AND HALLUCINATIONS: THE ATROPINE RISK
Lemaire Hurtel A.S.([email protected])*, Bodeau S., Bennis Y., Knapp A., Mayer C., Alvarez
J.C.
WOP 10
SUICIDE OF A NURSE IN A HOSPITAL ENVIRONMENT INVOLVING ANESTHETIC DRUGS
Aknouche F.([email protected])*
WOP 11
POISONOUS PLANTS AND ANCIENT HUNTERS: AN ANALYTICAL INVESTIGATION INTO
THE PRESENCE OF PLANT ALKALOIDS ON HUNTING TOOLS FROM INTERNATIONAL
MUSEUM COLLECTIONS
Carlin M.G.([email protected])*, Borgia V., Bowerbank S.
WOP 12
A HIDDEN KILLER?: PREGABALIN IN FATALITIES
Elliott S.([email protected])*
WOP 13
ETHYLPHENIDATE IN POST MORTEM CASES
Morley S.([email protected])*, Smith P., Cole R., Hikin L.
WOP 14
DEATHS INVOLVING ‘DOCTOR SHOPPING’ AND THE MISUSE OF PRESCRIPTION DRUGS
IN AUSTRALIA
Pilgrim J.([email protected])*, Dorward R., Dobbin M., Drummer O.
WOP 15
PAEDIATRIC DEATHS IN AUSTRALIA INVOLVING DIRECT DRUG TOXICITY 2003 - 2013
Jenkins E.([email protected])*, Gerostamoulos D., Caldicott D., Drummer O., Pilgrim J.
WOP 16
REPORTING A DEATH INVOLVING OPIUM CONSUMPTION IN A LEGAL POPPY FIELD IN
SPAIN
MartÍnez M.A.([email protected])*, Ballesteros S., Almarza E., Garijo J.
THURSDAY, September 3rd
SESSION 1 – In vivo Forensic Toxicology
8.30-10.30 am
ThOP 1
ACUTE INTOXICATION WITH CANNABIS IN A 12-MONTH-OLD GIRL: UNEXPECTED HIGH
CONCENTRATIONS OF THC AND THC-COOH
Jurado C.([email protected])*, Huertas T., Garcia S., Lopez--Oriol L., Moreno E.
ThOP 2
PASSIVE INHALATION OF CANNABIS SMOKE IS DRUG ADMINISTRATION
Cone E.([email protected])*, Bigelow G., Herrmann E., Mitchell J., Lodico C., Flegel R., Vandrey R.
ThOP 3
LIFE-THREATENING AMLODIPINE POISONING: THE RESPECTIVE ROLE OF VENOARTERIAL ECMO, LIPID RESCUE AND MARS© BASED ON THE ANALYSIS OF PLASMA
AMLODIPINE PHARMACOKINETICS
Soichot M.([email protected])*, Voicu S., Vodovar D., Deye N., Mégarbane B., Bourgogne E.
ThOP 4
USE OF BOTH THC-COOH FREE AND GLUCURONIDE TO ASSESS FREQUENCY OF
CANNABIS CONSUMPTION
Hädener M.([email protected])*, König S., Weinmann W., Giroud C., Martin Fabritius M.
ThOP 5
WHEN ECSTASY TURNS OUT TO BE CLOZAPINE AT A DANCE EVENT...
Patteet L.([email protected])*, Maudens K., Wille S., Blanckaert P., Hugo N., Calle P.
ThOP 6
DETECTION OF 3-METHYLMETHCATHINONE, PAROXETINE, AND CLOTIAZEPAM IN HEAD
HAIR AND/OR PUBIC HAIR SAMPLES BY LC/HR-MS ANALYSIS IN THREE DISTINCT
FORENSIC TOXICOLOGY CASES
Frison G.([email protected])*, Frasson S., Zancanaro F., Tedeschi G., Sciarrone R.
ThOP 7
A PROSPECTIVE PILOT STUDY OF MEASUREMENT OF BLOOD CONCENTRATIONS OF
ROUTINE MEDICATIONS IN PATIENTS TREATED IN THE INTENSIVE CARE UNIT
Kugelberg F.C.([email protected])*, Johansson A., Roman M., Kronstrand R., Lennborn U., Sandler
H., Ahlner J., Rubertsson S.
ThOP 8
EFFECTS OF RECENTLY-EMERGED SYNTHETIC CANNABINOIDS ON LOCOMOTOR
ACTIVITY IN MICE
Uchiyama N.([email protected])*, Aritake K., Kikura--Hanajiri R., Hakamatsuka T., Urade Y.
ThOP 9
DRUG SCREENING AND ILLICIT DRUG USE IN A TWO-SITE SOLID ORGAN TRANSPLANT
PRACTICE
Snozek C.([email protected])*, Langman L., Jannetto P.
SESSION 2 – Hair Analysis
11.00 am – 1.15 pm
ThOP 10
HYDROMORPHONE IN HAIR: AN INDICATOR OF HEROIN INTAKE VS CONTAMINATION?
Baumgartner M.R.([email protected])*, Madry M.M., Bosshard M.M., Kraemer T.
ThOP 11
UTILITY AND ALTERNATIVES OF COSMETICALLY TREATED HAIR FOR THE SENSITIVE
DETECTION OF DRUGS AND ALCOHOL
Agius R.([email protected])*, Dufaux B., Nadulski T., Kahl H.G.
ThOP 12
ESTABLISHMENT OF A DIAGNOSTIC PROBE FOR THE DISCRIMINATION OF EXOGENOUS
GHB IN HUMAN HAIR
Paradis--Tanguay L., Gilbert N., Vo Duy S., Sauvé S., Lajeunesse A.([email protected])*
ThOP 13
MASS SPECTROMETRY IMAGING FOR DEPICTING DRUG INCORPORATION INTO HAIR
Miki A.([email protected])*, Kamata T., Shima N., Sasaki K., Katagi M., Sato T., Tsuchihashi H.
ThOP 14
LONGITUDINAL SCANNING OF DRUGS OF ABUSE IN HAIR USING DIRECT ANALYSIS IN
REAL TIME (DART) HIGH RESOLUTION MASS SPECTROMETRY
Nielen M.([email protected])*, Duvivier W., Van Beek T., Sterk S.
ThOP 15
OCCUPATIONAL EXPOSURE TO KETAMINE DETECTED BY HAIR ANALYSIS: A
RETROSPECTIVE AND PROSPECTIVE STUDY
Favretto D.([email protected])*, Snenghi R., Vogliardi S., Donà A., El Mazloum R., Simoncello I.,
Ferrara S.D.
ThOP 16
WHEN KISSING CAN RESULT IN AN ADVERSE ANALYTICAL FINDING DURING DOPING
CONTROL: ABOUT 2 CASES WHERE HAIR TESTING WAS DETERMINANT FOR THE
ATHLETE
Kintz P.([email protected])*
ThOP 17
DETERMINATION OF HYDROXY METABOLITES OF COCAINE IN HAIR SAMPLES FOR
PROOF OF DEFINITE CONSUMPTION
Franz T.([email protected])*, Steinmetz S., Dame T., Schwarz G., Musshof F.
ThOP 18
INFLUENCE OF THERMAL HAIR STRAIGHTENING ON COCAINE IN HAIR
Ettlinger J., Yegles M.([email protected])*
SESSION 3 – New Technologies I
2.45 pm – 4.15 pm
ThOP 19
IDENTIFICATION OF NEW PSYCHOACTIVE SUBSTANCES AND THEIR METABOLITES
USING HIGH RESOLUTION MASS SPECTROMETRY FOLLOWING A NOVEL STRUCTURED
WORKFLOW
Kinyua J.([email protected])*, Maudens K., Negreira N., Brabanter N.D., Lanckmans K., Covaci
A., Van Nuijs A.
ThOP 20
RAPID DETERMINATION OF NEW PSYCHOACTIVE SUBSTANCES IN BIOLOGICAL
MATRICES USING AN AUTOMATED IN-LINE ITSP(TM) SPE-LC-MS/MS-SYSTEM
Lehmann S.([email protected])*, Kieliba T., Beike J., Rothschild M.A., Mercer--Chalmers-Bender K.
ThOP 21
QUANTIFICATION OF DESMETHYL METABOLITES BY UPLC WITH CORONA CHARGED
AEROSOL DETECTION USING THE PARENT DRUG FOR CALIBRATION
Viinamäki J.([email protected])*, Ojanperä I.
ThOP 22
COCAINE AND METABOLITES CONCENTRATIONS IN DRIED BLOOD SPOTS AND VENOUS
BLOOD AFTER CONTROLLED INTRAVENOUS COCAINE ADMINISTRATION
Ellefsen K.([email protected])*, Luiz Da Costa J., Concheiro M., Anizan S., Barnes A., Pirard S.,
Gorelick D., Huestis M.
ThOP 23
SUPPORTED LIQUID EXTRACTION (SLE) FOR THE ANALYSIS OF METHYLAMPHETAMINE,
METHYLENEDIOXYMETHYLAMPHETAMINE AND DELTA-9-TETRAHYDROCANNABINOL IN
ORAL FLUID AND BLOOD
Rositano J., Harpas P., Kostakis C., Scott T.([email protected])*
ThOP 24
SIMULTANEOUS DETERMINATION OF 40 NOVEL PSYCHOACTIVE STIMULANTS IN URINE
BY LIQUID CHROMATOGRAPHY HIGH-RESOLUTION MASS SPECTROMETRY AND
LIBRARY MATCHING
Concheiro M.([email protected])*, Castaneto M., Kronstrand R., Huestis M.A.
ThOP 25
DEFINITIVE MULTI-ANALYTE DRUG TESTING IN URINE BY UPLC-MS/MS: AN ALTERNATIVE
TO PRESUMPTIVE SCREENING BY IMMUNOASSAY
Rosano T.([email protected])*, Ohouo P., Leque J., Freeto S., Wood M.
ThOP 26
DETERMINATION OF MEDICAL AND ILLICIT DRUGS IN POST MORTEM DENTAL HARD
TISSUES AND COMPARISON WITH ANALYTICAL RESULTS FOR BODY FLUIDS AND HAIR
SAMPLES
Klima M.([email protected])*, Altenburger M.J., Kempf J., Auwärter V., Neukamm M.A.
SESSION 4 – New Psychoactive Substances II
(abuse
patterns
and identification)
4.30 pm – 6.00 pm
ThOP 27
DESIGNER STIMULANTS - EVOLVING ABUSE PATTERNS, 2011-2015
Uralets V.([email protected])*, Rana S., Ross W.
ThOP 28
TRENDS AND CHANGES IN THE SYNTHETIC CANNABINOID DRUGS MARKET IN ISRAEL
BETWEEN 2010-2014
Tepperberg M., Schallmach E.([email protected])*, Rotenberg M.
ThOP 29
NEW PSYCHOACTIVE SUBSTANCES: THE PERKS AND PITFALLS OF ON-LINE
PURCHASING
Button J.([email protected])*, Johansen J.E., Eriksson S., Liu H.
ThOP 30
FAST IDENTIFICATION OF NEW PSYCHOACTIVE SUBSTANCES IN COLLABORATION WITH
EUROPEAN CUSTOMS
Lobo Vicente J.([email protected])*, Chassaigne H., Reniero F., Holland V., Kolar K., Guillou C.
ThOP 31
IN SILICO PREDICTION OF AND IN VITRO METABOLISM STUDIES OF NEW DESIGNER
DRUGS 25I-NBOME AND 25I-NBOH
Nielsen L.M.(
[email protected])*, Holm N.B., Leth-Petersen S., Kristensen J.L., Gabel--Jensen
C., Olsen L., Linnet K.
ThOP 32
25I-NBOME - CASE REPORT AND METABOLISM
Grumann C.([email protected])*, Franz F., Hermanns--Clausen M., Kithinji J.,
Auwärter V.
FRIDAY, September 4th
SESSION 1 - New Technologies II
8.30 - 10.30 am
FOP 1
BRAIN DISTRIBUTION STUDIES OF ANTIPSYCHOTIC DRUG IN MOUSE WITH MALDI-TOF
MS IMAGING: HALOPERIDOL
Igarashi K.([email protected])*, Yoshida M., Nakanishi T.
FOP 2
A MULTICOMPONENT UPLC-Q-TOF METHOD FOR SCREENING OF PHARMACEUTICAL
COMPOUNDS IN POST MORTEM BLOOD- VALIDATION, DATA MINING STRATEGIES AND
RESULTS FROM ROUTINE ANALYSIS.
Liane V.H.([email protected])*, Svendsen K.O., Kristoffersen L.
FOP 3
HIGH SENSITIVITY/SPECIFICITY DETERMINATION OF CARBOHYDRATE-DEFICIENT
TRANSFERRIN (CDT) BY A NEW METHOD BASED ON HPLC SEPARATION WITH
FLUORESCENCE DETECTION
Sorio D., De Palo E.F., Bortolotti F., Tagliaro F.([email protected])*
FOP 4
ORBITRAP-BASED LC-HR-MS/MS STANDARD URINE SCREENING APPROACH: TRANSFER
TO BLOOD PLASMA EXEMPLIFIED FOR CARDIOVASCULAR DRUGS
Helfer A.G.([email protected])*, Michely J.A., Weber A.A., Meyer M.R., Maurer H.H.
FOP 5
UPLC-MS/MS METHOD FOR THE SIMULTANEOUS DETERMINATION OF 35 SUBSTANCES
INCLUDING MEDICINES AND DRUGS OF ABUSE ON DRIED BLOOD SPOTS APPLIED IN
FORENSIC TOXICOLOGY
Simões S.([email protected])*, Castañera A., Franco J.M., Dias M.J.
FOP 6
MICROWAVE-ASSISTED ON-SPOT DERIVATIZATION FOR THE GC-MS BASED
DETERMINATION OF POLAR LOW MOLECULAR WEIGHT MOLECULES -AMONGST WHICH
GHB AND BHB- IN DRIED BLOOD SPOTS
Sadones N.([email protected])*, Ghevel S., Lambert W.E., Stove C.P.
FOP 7
DETERMINATION OF SYNACTHEN® IN DRIED BLOOD SPOTS FOR DOPING CONTROL
ANALYSIS USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY
Tretzel L.([email protected])*, Thomas A., Geyer H., Delahaut P., Schaenzer W., Thevis M.
FOP 8
DEVELOPMENT OF A WORKFLOW FOR NON-TARGETED HIGH RESOLUTION ACCURATE
MASS SPECTROMETRY ANALYSIS IN FORENSIC TOXICOLOGY: A CASE STUDY IN NBOME
DETECTION
Cawley A.([email protected])*, Ganbat N., Ennis L., Smart C., Greer C., Keledjian J., Pasin D., Fu
S., Chen A.
SESSION 2 – post mortem Forensic Toxicology
11.00 am - 12.45 pm
FOP 9
A CLUSTER OF PARA-METHOXY-METHAMPHETAMINE (PMMA) RELATED FATALATIES
Kronstrand R.([email protected])*, Lindstedt D., Roman M., Thelander G.
FOP 10
THE GAS PROJECT : POSTMORTEM IMAGING AND ANALYSIS OF CARDIAC GASES HELP
TO DIAGNOSE THE CAUSE OF DEATH
Varlet V.([email protected])*, Smith F., Giuliani N., Egger C., Dominguez A., Chevallier C., Augsburger
M., Grabherr S.
FOP 11
DETECTION OF PSYCHOACTIVE SUBSTANCES ON HAIR AND MUSCLE SAMPLES AFTER
30 YEARS BY LC-MS/MS AND MALDI-LTQ ORBITRAP TECHNOLOGY WITH DRIED MATRIX
SPOT SAMPLING
Grata E., Sporkert F., Thomas A., Déglon J., Mottini N., Augsburger M., Pinorini
M.T.([email protected])*
FOP 12
THE SEARCH FOR A VOLATILE HUMAN SPECIFIC MARKER IN THE POST MORTEM
DECOMPOSITION PROCESS
Rosier E.(
[email protected])*, Loix S., Develter W., Van de Voorde W., Tytgat J., Cuypers E.
FOP 13
QUETIAPINE IN BRAIN TISSUE
Skov L.([email protected])*, Stybe Johansen S., Linnet K.
FOP 14
AUTOPSY AND TOXICOLOGY FINDINGS IN THREE CASES OF INTRAVENOUS INJECTION
OF ORAL TABLETS
Ritchey D.([email protected])*
FOP 15
FATAL COMBINATION WITH 3-METHYLMETHCATHINONE (3-MMC) AND GAMMAHYDROXYBUTYRIC ACID (GHB)
Jamey C.([email protected])*, Kintz P., Martrille L., Humbert L., Raul J.S.
FOP 16
TIME-DEPENDENT POSTMORTEM REDISTRIBUTION OF CENTRALLY ACTING
SUBSTANCES
Staeheli S.N.([email protected])*, Gascho D., Fornaro J., Laberke P., Steuer A.E., Kraemer T.